cmcmaster/rheumatology-biologics-dataset · Datasets at Hugging Face

pbs_code stringlengths 5 6	drug stringclasses 17 values	brand stringclasses 30 values	formulation stringclasses 37 values	indication stringclasses 8 values	treatment_phase stringclasses 57 values	streamlined_code stringclasses 33 values	online_application bool 2 classes	authority_method stringclasses 2 values	hospital_type stringclasses 3 values	schedule_code int64 3.47k 3.47k	schedule_year int64 2.02k 2.02k	schedule_month stringclasses 1 value
13686H	adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	First continuing treatment	14567	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
13686H	adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	First continuing treatment	14567	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
13686H	adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	First continuing treatment	14567	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
13686H	adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	rheumatoid arthritis	First continuing treatment	14567	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
13687J	etanercept	Brenzys	Injection 50 mg in 1 mL single use auto-injector, 4	rheumatoid arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13687J	etanercept	Brenzys	Injection 50 mg in 1 mL single use auto-injector, 4	rheumatoid arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13687J	etanercept	Brenzys	Injection 50 mg in 1 mL single use auto-injector, 4	rheumatoid arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13687J	etanercept	Brenzys	Injection 50 mg in 1 mL single use auto-injector, 4	rheumatoid arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12040Q	certolizumab pegol	Cimzia	Injection 200 mg in 1 mL single use pre-filled syringe	non-radiographic axial spondyloarthritis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12040Q	certolizumab pegol	Cimzia	Injection 200 mg in 1 mL single use pre-filled syringe	non-radiographic axial spondyloarthritis	Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12767Y	tocilizumab	Actemra ACTPen	Injection 162 mg in 0.9 mL single use pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
10897M	certolizumab pegol	Cimzia	Injection 200 mg in 1 mL single use pre-filled syringe	ankylosing spondylitis	Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13075E	infliximab	Remsima SC	Solution for injection 120 mg in 1 mL pre-filled pen	ankylosing spondylitis	Balance of supply (including switching formulation) where the full duration of treatment available under a particular treatment phase was not requested in the preceding prescription	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
14195D	anifrolumab	Saphnelo	Solution concentrate for I.V. infusion 300 mg in 2 mL	systemic lupus erythematosus	Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements	null	false	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
14195D	anifrolumab	Saphnelo	Solution concentrate for I.V. infusion 300 mg in 2 mL	systemic lupus erythematosus	Continuing or recommencement of treatment (within 12 months of a treatment break)	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
14195D	anifrolumab	Saphnelo	Solution concentrate for I.V. infusion 300 mg in 2 mL	systemic lupus erythematosus	Initial treatment	null	false	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
11319R	certolizumab pegol	Cimzia	Solution for injection 200 mg in 1 mL pre-filled pen	ankylosing spondylitis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
11319R	certolizumab pegol	Cimzia	Solution for injection 200 mg in 1 mL pre-filled pen	ankylosing spondylitis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
11319R	certolizumab pegol	Cimzia	Solution for injection 200 mg in 1 mL pre-filled pen	ankylosing spondylitis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
11742B	tocilizumab	Actemra ACTPen	Injection 162 mg in 0.9 mL single use pre-filled pen	juvenile idiopathic arthritis	Continuing treatment	14150	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
10894J	secukinumab	Cosentyx	Injection 150 mg in 1 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
10894J	secukinumab	Cosentyx	Injection 150 mg in 1 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
10894J	secukinumab	Cosentyx	Injection 150 mg in 1 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
5284D	adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
5284D	adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
5284D	adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
5284D	adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
5284D	adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
5284D	adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
5284D	adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
5284D	adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
5284D	adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
5284D	adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
5284D	adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
5284D	adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
11318Q	certolizumab pegol	Cimzia	Solution for injection 200 mg in 1 mL pre-filled pen	ankylosing spondylitis	Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13725J	abatacept	Orencia	Powder for I.V. infusion 250 mg	rheumatoid arthritis	Subsequent continuing treatment	14604	true	STREAMLINED	Public	3,471	2,024	NOVEMBER
11323Y	certolizumab pegol	Cimzia	Solution for injection 200 mg in 1 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
11323Y	certolizumab pegol	Cimzia	Solution for injection 200 mg in 1 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
11323Y	certolizumab pegol	Cimzia	Solution for injection 200 mg in 1 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13226D	adalimumab	Yuflyma	Injection 40 mg in 0.4 mL pre-filled pen	ankylosing spondylitis	Subsequent continuing treatment	14701	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
13226D	adalimumab	Adalicip	Injection 40 mg in 0.4 mL pre-filled pen	ankylosing spondylitis	Subsequent continuing treatment	14701	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
13226D	adalimumab	Hadlima	Injection 40 mg in 0.4 mL pre-filled pen	ankylosing spondylitis	Subsequent continuing treatment	14701	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
13226D	adalimumab	Yuflyma	Injection 40 mg in 0.4 mL pre-filled pen	ankylosing spondylitis	First continuing treatment	14683	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
13226D	adalimumab	Adalicip	Injection 40 mg in 0.4 mL pre-filled pen	ankylosing spondylitis	First continuing treatment	14683	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
13226D	adalimumab	Hadlima	Injection 40 mg in 0.4 mL pre-filled pen	ankylosing spondylitis	First continuing treatment	14683	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
1221G	abatacept	Orencia	Injection 125 mg in 1 mL single dose pre-filled syringe	rheumatoid arthritis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
1221G	abatacept	Orencia	Injection 125 mg in 1 mL single dose pre-filled syringe	rheumatoid arthritis	First continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
11693K	abatacept	Orencia ClickJect	Injection 125 mg in 1 mL single dose autoinjector	rheumatoid arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
11693K	abatacept	Orencia ClickJect	Injection 125 mg in 1 mL single dose autoinjector	rheumatoid arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
11693K	abatacept	Orencia ClickJect	Injection 125 mg in 1 mL single dose autoinjector	rheumatoid arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
11693K	abatacept	Orencia ClickJect	Injection 125 mg in 1 mL single dose autoinjector	rheumatoid arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12802T	tocilizumab	Actemra	Concentrate for injection 400 mg in 20 mL	juvenile idiopathic arthritis	Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
12802T	tocilizumab	Actemra	Concentrate for injection 400 mg in 20 mL	juvenile idiopathic arthritis	Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab)	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
13685G	tocilizumab	Actemra Subcutaneous Injection	Injection 162 mg in 0.9 mL single use pre-filled syringe	rheumatoid arthritis	Subsequent continuing treatment	14499	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
12787B	tocilizumab	Actemra	Concentrate for injection 80 mg in 4 mL	rheumatoid arthritis	Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)	null	true	AUTHORITY_REQUIRED	Private	3,471	2,024	NOVEMBER
13723G	infliximab	Inflectra	Powder for I.V. infusion 100 mg	rheumatoid arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
13723G	infliximab	Renflexis	Powder for I.V. infusion 100 mg	rheumatoid arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
13723G	infliximab	Inflectra	Powder for I.V. infusion 100 mg	rheumatoid arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
13723G	infliximab	Renflexis	Powder for I.V. infusion 100 mg	rheumatoid arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
13723G	infliximab	Inflectra	Powder for I.V. infusion 100 mg	rheumatoid arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
13723G	infliximab	Renflexis	Powder for I.V. infusion 100 mg	rheumatoid arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
13723G	infliximab	Inflectra	Powder for I.V. infusion 100 mg	rheumatoid arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
13723G	infliximab	Renflexis	Powder for I.V. infusion 100 mg	rheumatoid arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
12400P	adalimumab	Hadlima	Injection 40 mg in 0.4 mL pre-filled syringe	rheumatoid arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12400P	adalimumab	Yuflyma	Injection 40 mg in 0.4 mL pre-filled syringe	rheumatoid arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12400P	adalimumab	Adalicip	Injection 40 mg in 0.4 mL pre-filled syringe	rheumatoid arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12400P	adalimumab	Humira	Injection 40 mg in 0.4 mL pre-filled syringe	rheumatoid arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12400P	adalimumab	Hadlima	Injection 40 mg in 0.4 mL pre-filled syringe	rheumatoid arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12400P	adalimumab	Yuflyma	Injection 40 mg in 0.4 mL pre-filled syringe	rheumatoid arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12400P	adalimumab	Adalicip	Injection 40 mg in 0.4 mL pre-filled syringe	rheumatoid arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12400P	adalimumab	Humira	Injection 40 mg in 0.4 mL pre-filled syringe	rheumatoid arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12400P	adalimumab	Hadlima	Injection 40 mg in 0.4 mL pre-filled syringe	rheumatoid arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12400P	adalimumab	Yuflyma	Injection 40 mg in 0.4 mL pre-filled syringe	rheumatoid arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12400P	adalimumab	Adalicip	Injection 40 mg in 0.4 mL pre-filled syringe	rheumatoid arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12400P	adalimumab	Humira	Injection 40 mg in 0.4 mL pre-filled syringe	rheumatoid arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12400P	adalimumab	Hadlima	Injection 40 mg in 0.4 mL pre-filled syringe	rheumatoid arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12400P	adalimumab	Yuflyma	Injection 40 mg in 0.4 mL pre-filled syringe	rheumatoid arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12400P	adalimumab	Adalicip	Injection 40 mg in 0.4 mL pre-filled syringe	rheumatoid arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12400P	adalimumab	Humira	Injection 40 mg in 0.4 mL pre-filled syringe	rheumatoid arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
14285W	adalimumab	Abrilada	Injection 20 mg in 0.4 mL pre-filled syringe	juvenile idiopathic arthritis	Continuing treatment	14107	true	STREAMLINED	Private	3,471	2,024	NOVEMBER
12355G	adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Continuing treatment	14136	true	STREAMLINED	Public	3,471	2,024	NOVEMBER
12355G	adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Continuing treatment	14136	true	STREAMLINED	Public	3,471	2,024	NOVEMBER
12355G	adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Continuing treatment	14136	true	STREAMLINED	Public	3,471	2,024	NOVEMBER
12355G	adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Continuing treatment	14136	true	STREAMLINED	Public	3,471	2,024	NOVEMBER
8778B	etanercept	Enbrel	Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL	ankylosing spondylitis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
8778B	etanercept	Enbrel	Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL	ankylosing spondylitis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
8778B	etanercept	Enbrel	Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL	ankylosing spondylitis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
8778B	etanercept	Enbrel	Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL	ankylosing spondylitis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
10767Q	ustekinumab	Stelara	Injection 45 mg in 0.5 mL	psoriatic arthritis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
10767Q	ustekinumab	Stelara	Injection 45 mg in 0.5 mL	psoriatic arthritis	Continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
11498E	infliximab	Renflexis	Powder for I.V. infusion 100 mg	psoriatic arthritis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Private	3,471	2,024	NOVEMBER
11498E	infliximab	Remicade	Powder for I.V. infusion 100 mg	psoriatic arthritis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Private	3,471	2,024	NOVEMBER
11498E	infliximab	Inflectra	Powder for I.V. infusion 100 mg	psoriatic arthritis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Private	3,471	2,024	NOVEMBER
12027B	certolizumab pegol	Cimzia	Solution for injection 200 mg in 1 mL pre-filled pen	non-radiographic axial spondyloarthritis	Initial treatment - Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12027B	certolizumab pegol	Cimzia	Solution for injection 200 mg in 1 mL pre-filled pen	non-radiographic axial spondyloarthritis	Initial treatment - Initial 1 (New patient)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12027B	certolizumab pegol	Cimzia	Solution for injection 200 mg in 1 mL pre-filled pen	non-radiographic axial spondyloarthritis	Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
10137M	certolizumab pegol	Cimzia	Injection 200 mg in 1 mL single use pre-filled syringe	ankylosing spondylitis	Continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
10137M	certolizumab pegol	Cimzia	Injection 200 mg in 1 mL single use pre-filled syringe	ankylosing spondylitis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13332Q	etanercept	Enbrel	Injections 50 mg in 1 mL single use pre-filled syringes, 4	juvenile idiopathic arthritis	Continuing treatment	14155	true	STREAMLINED	Private	3,471	2,024	NOVEMBER

13686H

adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled pen

rheumatoid arthritis

First continuing treatment

14567

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

13686H

adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled pen

rheumatoid arthritis

First continuing treatment

14567

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

13686H

adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled pen

rheumatoid arthritis

First continuing treatment

14567

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

13686H

adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled pen

rheumatoid arthritis

First continuing treatment

14567

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

13687J

etanercept

Brenzys

Injection 50 mg in 1 mL single use auto-injector, 4

rheumatoid arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13687J

etanercept

Brenzys

Injection 50 mg in 1 mL single use auto-injector, 4

rheumatoid arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13687J

etanercept

Brenzys

Injection 50 mg in 1 mL single use auto-injector, 4

rheumatoid arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13687J

etanercept

Brenzys

Injection 50 mg in 1 mL single use auto-injector, 4

rheumatoid arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12040Q

certolizumab pegol

Cimzia

Injection 200 mg in 1 mL single use pre-filled syringe

non-radiographic axial spondyloarthritis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12040Q

certolizumab pegol

Cimzia

Injection 200 mg in 1 mL single use pre-filled syringe

non-radiographic axial spondyloarthritis

Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12767Y

tocilizumab

Actemra ACTPen

Injection 162 mg in 0.9 mL single use pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

10897M

certolizumab pegol

Cimzia

Injection 200 mg in 1 mL single use pre-filled syringe

ankylosing spondylitis

Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13075E

infliximab

Remsima SC

Solution for injection 120 mg in 1 mL pre-filled pen

ankylosing spondylitis

Balance of supply (including switching formulation) where the full duration of treatment available under a particular treatment phase was not requested in the preceding prescription

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

14195D

anifrolumab

Saphnelo

Solution concentrate for I.V. infusion 300 mg in 2 mL

systemic lupus erythematosus

Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements

null

false

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

14195D

anifrolumab

Saphnelo

Solution concentrate for I.V. infusion 300 mg in 2 mL

systemic lupus erythematosus

Continuing or recommencement of treatment (within 12 months of a treatment break)

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

14195D

anifrolumab

Saphnelo

Solution concentrate for I.V. infusion 300 mg in 2 mL

systemic lupus erythematosus

Initial treatment

null

false

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

11319R

certolizumab pegol

Cimzia

Solution for injection 200 mg in 1 mL pre-filled pen

ankylosing spondylitis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

11319R

certolizumab pegol

Cimzia

Solution for injection 200 mg in 1 mL pre-filled pen

ankylosing spondylitis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

11319R

certolizumab pegol

Cimzia

Solution for injection 200 mg in 1 mL pre-filled pen

ankylosing spondylitis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

11742B

tocilizumab

Actemra ACTPen

Injection 162 mg in 0.9 mL single use pre-filled pen

juvenile idiopathic arthritis

Continuing treatment

14150

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

10894J

secukinumab

Cosentyx

Injection 150 mg in 1 mL pre-filled pen

psoriatic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

10894J

secukinumab

Cosentyx

Injection 150 mg in 1 mL pre-filled pen

psoriatic arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

10894J

secukinumab

Cosentyx

Injection 150 mg in 1 mL pre-filled pen

psoriatic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

5284D

adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Subsequent continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

5284D

adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Subsequent continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

5284D

adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Subsequent continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

5284D

adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Subsequent continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

5284D

adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

5284D

adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

5284D

adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

5284D

adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

5284D

adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

5284D

adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

5284D

adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

5284D

adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

11318Q

certolizumab pegol

Cimzia

Solution for injection 200 mg in 1 mL pre-filled pen

ankylosing spondylitis

Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13725J

abatacept

Orencia

Powder for I.V. infusion 250 mg

rheumatoid arthritis

Subsequent continuing treatment

14604

true

STREAMLINED

Public

3,471

2,024

NOVEMBER

11323Y

certolizumab pegol

Cimzia

Solution for injection 200 mg in 1 mL pre-filled pen

psoriatic arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

11323Y

certolizumab pegol

Cimzia

Solution for injection 200 mg in 1 mL pre-filled pen

psoriatic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

11323Y

certolizumab pegol

Cimzia

Solution for injection 200 mg in 1 mL pre-filled pen

psoriatic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13226D

adalimumab

Yuflyma

Injection 40 mg in 0.4 mL pre-filled pen

ankylosing spondylitis

Subsequent continuing treatment

14701

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

13226D

adalimumab

Adalicip

Injection 40 mg in 0.4 mL pre-filled pen

ankylosing spondylitis

Subsequent continuing treatment

14701

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

13226D

adalimumab

Hadlima

Injection 40 mg in 0.4 mL pre-filled pen

ankylosing spondylitis

Subsequent continuing treatment

14701

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

13226D

adalimumab

Yuflyma

Injection 40 mg in 0.4 mL pre-filled pen

ankylosing spondylitis

First continuing treatment

14683

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

13226D

adalimumab

Adalicip

Injection 40 mg in 0.4 mL pre-filled pen

ankylosing spondylitis

First continuing treatment

14683

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

13226D

adalimumab

Hadlima

Injection 40 mg in 0.4 mL pre-filled pen

ankylosing spondylitis

First continuing treatment

14683

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

1221G

abatacept

Orencia

Injection 125 mg in 1 mL single dose pre-filled syringe

rheumatoid arthritis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

1221G

abatacept

Orencia

Injection 125 mg in 1 mL single dose pre-filled syringe

rheumatoid arthritis

First continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

11693K

abatacept

Orencia ClickJect

Injection 125 mg in 1 mL single dose autoinjector

rheumatoid arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

11693K

abatacept

Orencia ClickJect

Injection 125 mg in 1 mL single dose autoinjector

rheumatoid arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

11693K

abatacept

Orencia ClickJect

Injection 125 mg in 1 mL single dose autoinjector

rheumatoid arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

11693K

abatacept

Orencia ClickJect

Injection 125 mg in 1 mL single dose autoinjector

rheumatoid arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12802T

tocilizumab

Actemra

Concentrate for injection 400 mg in 20 mL

juvenile idiopathic arthritis

Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

12802T

tocilizumab

Actemra

Concentrate for injection 400 mg in 20 mL

juvenile idiopathic arthritis

Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab)

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

13685G

tocilizumab

Actemra Subcutaneous Injection

Injection 162 mg in 0.9 mL single use pre-filled syringe

rheumatoid arthritis

Subsequent continuing treatment

14499

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

12787B

tocilizumab

Actemra

Concentrate for injection 80 mg in 4 mL

rheumatoid arthritis

Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)

null

true

AUTHORITY_REQUIRED

Private

3,471

2,024

NOVEMBER

13723G

infliximab

Inflectra

Powder for I.V. infusion 100 mg

rheumatoid arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

13723G

infliximab

Renflexis

Powder for I.V. infusion 100 mg

rheumatoid arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

13723G

infliximab

Inflectra

Powder for I.V. infusion 100 mg

rheumatoid arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

13723G

infliximab

Renflexis

Powder for I.V. infusion 100 mg

rheumatoid arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

13723G

infliximab

Inflectra

Powder for I.V. infusion 100 mg

rheumatoid arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

13723G

infliximab

Renflexis

Powder for I.V. infusion 100 mg

rheumatoid arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

13723G

infliximab

Inflectra

Powder for I.V. infusion 100 mg

rheumatoid arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

13723G

infliximab

Renflexis

Powder for I.V. infusion 100 mg

rheumatoid arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

12400P

adalimumab

Hadlima

Injection 40 mg in 0.4 mL pre-filled syringe

rheumatoid arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12400P

adalimumab

Yuflyma

Injection 40 mg in 0.4 mL pre-filled syringe

rheumatoid arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12400P

adalimumab

Adalicip

Injection 40 mg in 0.4 mL pre-filled syringe

rheumatoid arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12400P

adalimumab

Humira

Injection 40 mg in 0.4 mL pre-filled syringe

rheumatoid arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12400P

adalimumab

Hadlima

Injection 40 mg in 0.4 mL pre-filled syringe

rheumatoid arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12400P

adalimumab

Yuflyma

Injection 40 mg in 0.4 mL pre-filled syringe

rheumatoid arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12400P

adalimumab

Adalicip

Injection 40 mg in 0.4 mL pre-filled syringe

rheumatoid arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12400P

adalimumab

Humira

Injection 40 mg in 0.4 mL pre-filled syringe

rheumatoid arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12400P

adalimumab

Hadlima

Injection 40 mg in 0.4 mL pre-filled syringe

rheumatoid arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12400P

adalimumab

Yuflyma

Injection 40 mg in 0.4 mL pre-filled syringe

rheumatoid arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12400P

adalimumab

Adalicip

Injection 40 mg in 0.4 mL pre-filled syringe

rheumatoid arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12400P

adalimumab

Humira

Injection 40 mg in 0.4 mL pre-filled syringe

rheumatoid arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12400P

adalimumab

Hadlima

Injection 40 mg in 0.4 mL pre-filled syringe

rheumatoid arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12400P

adalimumab

Yuflyma

Injection 40 mg in 0.4 mL pre-filled syringe

rheumatoid arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12400P

adalimumab

Adalicip

Injection 40 mg in 0.4 mL pre-filled syringe

rheumatoid arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12400P

adalimumab

Humira

Injection 40 mg in 0.4 mL pre-filled syringe

rheumatoid arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

14285W

adalimumab

Abrilada

Injection 20 mg in 0.4 mL pre-filled syringe

juvenile idiopathic arthritis

Continuing treatment

14107

true

STREAMLINED

Private

3,471

2,024

NOVEMBER

12355G

adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Continuing treatment

14136

true

STREAMLINED

Public

3,471

2,024

NOVEMBER

12355G

adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Continuing treatment

14136

true

STREAMLINED

Public

3,471

2,024

NOVEMBER

12355G

adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Continuing treatment

14136

true

STREAMLINED

Public

3,471

2,024

NOVEMBER

12355G

adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Continuing treatment

14136

true

STREAMLINED

Public

3,471

2,024

NOVEMBER

8778B

etanercept

Enbrel

Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL

ankylosing spondylitis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

8778B

etanercept

Enbrel

Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL

ankylosing spondylitis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

8778B

etanercept

Enbrel

Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL

ankylosing spondylitis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

8778B

etanercept

Enbrel

Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL

ankylosing spondylitis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

10767Q

ustekinumab

Stelara

Injection 45 mg in 0.5 mL

psoriatic arthritis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

10767Q

ustekinumab

Stelara

Injection 45 mg in 0.5 mL

psoriatic arthritis

Continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

11498E

infliximab

Renflexis

Powder for I.V. infusion 100 mg

psoriatic arthritis

Subsequent continuing treatment

null

false

AUTHORITY_REQUIRED

Private

3,471

2,024

NOVEMBER

11498E

infliximab

Remicade

Powder for I.V. infusion 100 mg

psoriatic arthritis

Subsequent continuing treatment

null

false

AUTHORITY_REQUIRED

Private

3,471

2,024

NOVEMBER

11498E

infliximab

Inflectra

Powder for I.V. infusion 100 mg

psoriatic arthritis

Subsequent continuing treatment

null

false

AUTHORITY_REQUIRED

Private

3,471

2,024

NOVEMBER

12027B

certolizumab pegol

Cimzia

Solution for injection 200 mg in 1 mL pre-filled pen

non-radiographic axial spondyloarthritis

Initial treatment - Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12027B

certolizumab pegol

Cimzia

Solution for injection 200 mg in 1 mL pre-filled pen

non-radiographic axial spondyloarthritis

Initial treatment - Initial 1 (New patient)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12027B

certolizumab pegol

Cimzia

Solution for injection 200 mg in 1 mL pre-filled pen

non-radiographic axial spondyloarthritis

Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

10137M

certolizumab pegol

Cimzia

Injection 200 mg in 1 mL single use pre-filled syringe

ankylosing spondylitis

Continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

10137M

certolizumab pegol

Cimzia

Injection 200 mg in 1 mL single use pre-filled syringe

ankylosing spondylitis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13332Q

etanercept

Enbrel

Injections 50 mg in 1 mL single use pre-filled syringes, 4

juvenile idiopathic arthritis

Continuing treatment

14155

true

STREAMLINED

Private

3,471

2,024

NOVEMBER

Datasets:

cmcmaster
/

rheumatology-biologics-dataset

Space using cmcmaster/rheumatology-biologics-dataset 1